06:28 AM EDT, 03/12/2026 (MT Newswires) -- Gyre Therapeutics ( GYRE ) reported a Q4 net loss Thursday of $0.02 per diluted share, compared with breakeven a year earlier.

Three analysts polled by FactSet expected earnings of $0.06 per share.

Revenue for the quarter ended Dec. 31 was $37.2 million, up from $27.9 million a year earlier. Three analysts surveyed by FactSet expected $35.4 million.

As of Dec. 31, the company said it had $75.9 million in cash, cash equivalents, short-term and long-term bank deposits.

For full year 2026, Gyre said it expects revenue of $100.5 million to $111.0 million. Three analysts polled by FactSet expect $148 million.

Gyre shares were down more than 2% in Thursday pre-bell activity.